+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hansa Biopharma AB (HNSA) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 53 Pages
  • May 2023
  • GlobalData
  • ID: 1367953
Hansa Biopharma AB (HNSA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Hansa Biopharma AB (Hansa Biopharma) focuses on the development of novel immunomodulatory enzymes for transplantation, gene therapy, cancer and acute autoimmune diseases. The company's lead project, imlifidase is a proprietary antibody cleaving enzyme for kidney transplant patients which is protected by 6 patent families. Its preclinical assets include NiceR for recurring treatment in autoimmune disease, transplantation, and cancer; and EnzE, cancer immunotherapy. Hansa Biopharma offers a novel diagnostic method HBP-assay (serum quantification of Heparin Binding Protein) to help predict severe sepsis in patients with infectious disease symptoms. The company has out-licensed its HBP-assay (serum quantification of Heparin-Binding Protein), a novel diagnostic method to help predict severe sepsis in patients with infectious disease symptoms to Axis-Shield Diagnostics. It has its operations in Other European Countries and the US. Hansa Biopharma is headquartered in Lund, Sweden.

Hansa Biopharma AB Key Recent Developments

  • Apr 20, 2023: Hansa Biopharma interim report January-March 2023
  • Apr 20, 2023: Hansa Biopharma AB: Hansa Biopharma interim report January-March 2023
  • Apr 14, 2023: Hansa Biopharma to host conference call to provide interim results for January-March 2023 and a Business Update
  • Mar 30, 2023: Hansa Biopharma publishes Annual Report 2022

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Hansa Biopharma AB - Key Facts
  • Hansa Biopharma AB - Key Employees
  • Hansa Biopharma AB - Key Employee Biographies
  • Hansa Biopharma AB - Major Products and Services
  • Hansa Biopharma AB - History
  • Hansa Biopharma AB - Company Statement
  • Hansa Biopharma AB - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Hansa Biopharma AB - Business Description
  • R&D Overview
  • Hansa Biopharma AB - Corporate Strategy
  • Hansa Biopharma AB - SWOT Analysis
  • SWOT Analysis - Overview
  • Hansa Biopharma AB - Strengths
  • Hansa Biopharma AB - Weaknesses
  • Hansa Biopharma AB - Opportunities
  • Hansa Biopharma AB - Threats
  • Hansa Biopharma AB - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Hansa Biopharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Hansa Biopharma AB, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Hansa Biopharma AB, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Apr 20, 2023: Hansa Biopharma interim report January-March 2023
  • Apr 20, 2023: Hansa Biopharma AB: Hansa Biopharma interim report January-March 2023
  • Apr 14, 2023: Hansa Biopharma to host conference call to provide interim results for January-March 2023 and a Business Update
  • Mar 30, 2023: Hansa Biopharma publishes Annual Report 2022
  • Mar 03, 2023: Matthew Shaulis appointed Chief Commercial Officer and US President of Hansa Biopharma
  • Mar 03, 2023: Matthew Shaulis appointed Chief Commercial Officer and US President of Hansa Biopharma
  • Feb 02, 2023: Hansa Biopharma Announces Year-end report January-December 2022
  • Jan 30, 2023: Hansa Biopharma announces planned departure of Chief Scientific Officer Christian Kjellman
  • Dec 30, 2022: Hansa Biopharma: Increase of the number of shares and votes
  • Oct 20, 2022: Hansa Biopharma Interim report January-September 2022
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Hansa Biopharma AB, Key Facts
  • Hansa Biopharma AB, Key Employees
  • Hansa Biopharma AB, Key Employee Biographies
  • Hansa Biopharma AB, Major Products and Services
  • Hansa Biopharma AB, History
  • Hansa Biopharma AB, Subsidiaries
  • Hansa Biopharma AB, Key Competitors
  • Hansa Biopharma AB, Ratios based on current share price
  • Hansa Biopharma AB, Annual Ratios
  • Hansa Biopharma AB, Interim Ratios
  • Hansa Biopharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Hansa Biopharma AB, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Hansa Biopharma AB, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Hansa Biopharma AB, Performance Chart (2018 - 2022)
  • Hansa Biopharma AB, Ratio Charts
  • Hansa Biopharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Hansa Biopharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Samples

Loading
LOADING...

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Diamyd Medical AB
  • Active Biotech AB
  • Swedish Orphan Biovitrum AB
  • BioInvent International AB
  • Calliditas Therapeutics AB